Charge Altering Releable Transporters for In vivo mRNA delivery to immune cells and its application for cancer vaccine development

The development of RNA drugs has reached an inflection point, paving the way for a new wave of precision gene therapies to treat undruggable diseases. Engineering non-viral RNA delivery technologies to meet the need for gene therapies targeted to specific cell-types or organs beyond hepatocytes remains a challenge. Here we report on a new class of materials refered Charge Altering Releasable Transporters (CARTs) for functional mRNA delivery to immune cells in spleen and its potential application in the development of cancer vaccines.